Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

IOBT

IO Biotech Inc

Nov 26 • 04:00PM ET

0.7340

+0.0068 0.94 %

Healthcare • Biotechnology • Denmark • NASD

Peers: ARGX FATE TVRD APLS AFMD KURA ANAB ALLK ALXO CTMX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.34	Insider Own	19.80%	Shs Outstand	69.69M	Perf Week	-2.34%
Market Cap	52.81M	Forward P/E	-	EPS next Y	-0.44	Insider Trans	0.11%	Shs Float	57.70M	Perf Month	-18.53%
Enterprise Value	40.27M	PEG	-	EPS next Q	-0.16	Inst Own	37.33%	Short Float	4.21%	Perf Quarter	-53.54%
Income	-88.35M	P/S	-	EPS this Y	24.97%	Inst Trans	-13.66%	Short Ratio	0.66	Perf Half Y	-39.34%
Sales	0.00M	P/B	56.16	EPS next Y	59.38%	ROA	-136.03%	Short Interest	2.43M	Perf YTD	-20.22%
Book/sh	0.01	P/C	1.72	EPS next 5Y	31.70%	ROE	-240.48%	52W High	2.79 -73.69%	Perf Year	3.69%
Cash/sh	0.43	P/FCF	-	EPS past 3/5Y	17.72% -25.33%	ROIC	-484.32%	52W Low	0.32 126.96%	Perf 3Y	-71.10%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.81% 13.56%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	2.36%	Oper. Margin	-	ATR (14)	0.11	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.01	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	43.88	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	2.01	EPS Q/Q	65.65%	SMA20	-11.14%	Beta	0.52	Target Price	5.35
Payout	-	Debt/Eq	19.91	Sales Q/Q	-	SMA50	-14.88%	Rel Volume	0.11	Prev Close	0.73
Employees	80	LT Debt/Eq	19.04	Earnings	Nov 14 BMO	SMA200	-40.07%	Avg Volume	3.68M	Price	0.73
IPO	Nov 05, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	59.88% -	Trades		Volume	388,589	Change	0.94%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-25	Downgrade	TD Cowen	Buy → Hold
Sep-30-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$0.39

Nov-26-25 10:46AM	IO Biotech Announces Participation in Upcoming December Investor Conferences (GlobeNewswire)
Nov-19-25 12:00PM	IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's Why (Zacks) -8.90%
Nov-14-25 08:05AM	IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire)
Nov-12-25 08:30AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire) -6.00%
Nov-07-25 09:00AM	IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (GlobeNewswire) +6.96%
08:30AM	Loading…
Oct-27-25 08:30AM	Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology (PR Newswire) -9.11%
Oct-20-25 02:30AM	IO Biotech Presents Phase 3 Results for Cylembio plus KEYTRUDA (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025 (GlobeNewswire) +25.18%
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire) +6.83%
Oct-01-25 06:00AM	FDA officials comments spark Aurinia sell-off; Halozyme buys a biotech (BioPharma Dive)
Sep-29-25 07:05AM	IO Biotech Provides Update Following Pre-BLA Meeting with FDA (GlobeNewswire) -76.89%
Sep-23-25 08:05AM	IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025 (GlobeNewswire) +7.38%
Sep-15-25 08:30AM	Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth (PR Newswire) -11.54%
Sep-04-25 08:05AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Sep-03-25 12:00PM	IO Biotech, Inc. (IOBT) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-26-25 08:39AM	H.C. Wainwright Reiterates Buy Rating on IO Biotech, Keeps PT at $14 (Insider Monkey)
10:30AM	Loading…
Aug-18-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-14-25 04:05PM	IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights (GlobeNewswire) +68.75%
12:30PM	Biotech Stocks Rally as Oncology Market Targets $866B by 2034 (PR Newswire)
Aug-11-25 01:23PM	IO Biotech to pursue cancer vaccine approval despite Phase III miss (Clinical Trials Arena) -41.99%
10:30AM	BC-Most Active Stocks (Associated Press Finance)
08:02AM	IO Biotech sees path forward for skin cancer vaccine despite study setback (BioPharma Dive)
08:00AM	IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio plus KEYTRUDA (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed (GlobeNewswire)
Aug-10-25 08:00AM	IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire)
May-28-25 09:55AM	IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
May-20-25 08:05AM	IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 12:11PM	IO Biotech price target raised to $14 from $12 at H.C. Wainwright (TipRanks)
May-14-25 08:05AM	IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Apr-26-25 03:05PM	IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-25-25 01:00PM	IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 (GlobeNewswire)
Mar-25-25 04:35PM	IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.00%
08:00AM	Loading…
Mar-18-25 08:00AM	IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 (GlobeNewswire)
Mar-04-25 04:17PM	IO Biotech Reports 2024 Business Highlights (GlobeNewswire) +5.91%
Feb-23-25 12:07PM	IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference (GlobeNewswire)
Feb-20-25 08:05AM	IO Biotech to Present at the 45th Annual Cowen Health Care Conference (GlobeNewswire) +11.00%
Feb-04-25 08:05AM	IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate (GlobeNewswire) +6.74%
Jan-10-25 11:10AM	IO Biotech enrols all subjects in Phase II trial of cancer combination therapy (Clinical Trials Arena)
Jan-09-25 08:05AM	IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer (GlobeNewswire)
Dec-20-24 08:05AM	IO Biotech secures up to 57.5 million in debt financing from the European Investment Bank (GlobeNewswire)
Nov-12-24 07:05AM	IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) -11.68%
Nov-11-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-07-24 10:00AM	IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study (GlobeNewswire) +6.03%
Oct-04-24 09:00AM	IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting (GlobeNewswire) +13.86%
Sep-14-24 02:30AM	IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer (GlobeNewswire)
Sep-02-24 06:53AM	IO Biotechs melanoma treatment trial to continue after IDMC review (Clinical Trials Arena)
Aug-30-24 04:05PM	IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma (GlobeNewswire) -33.33%
Aug-26-24 04:05PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-13-24 07:05AM	IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire) +17.69%
Jul-25-24 04:05PM	IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024 (GlobeNewswire)
Jul-04-24 10:01AM	3 Undervalued Biotech Gems With 200%+ Analyst Price Targets (InvestorPlace)
May-23-24 08:30AM	IO Biotech to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 01:54PM	IOBT Stock Earnings: IO Biotech Beats EPS for Q1 2024 (InvestorPlace)
07:55AM	IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights (GlobeNewswire)
Apr-24-24 04:30PM	IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-15-24 08:30AM	IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness (GlobeNewswire)
Apr-09-24 12:00PM	IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103 (GlobeNewswire)
Apr-05-24 08:30AM	IO Biotech Appoints Faical Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
08:30AM	IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer (GlobeNewswire)
Mar-07-24 02:01PM	IO Biotech Inc (IOBT) Reports Year-End Financial Results and Progress in Clinical Trials (GuruFocus.com) +6.63%
Mar-06-24 04:11PM	IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-05-24 10:52PM	IOBT Stock Earnings: IO Biotech Misses EPS for Q4 2023 (InvestorPlace)
04:40PM	IO Biotech Announces 2023 Fourth-Quarter and Year-End Results (GlobeNewswire)
Feb-26-24 04:05PM	IO Biotech to Present at 44th Annual Cowen Health Care Conference (GlobeNewswire)
Dec-21-23 08:30AM	IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial (GlobeNewswire)
Nov-13-23 08:12AM	IO Biotech Announces 2023 Third Quarter Results (GlobeNewswire)
08:00AM	IO Biotech Appoints Helen Collins, MD, to its Board of Directors (GlobeNewswire)
Nov-10-23 08:00AM	IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma (GlobeNewswire)
Nov-08-23 04:30PM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-23 08:30AM	IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-24-23 12:30PM	10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +8.38%
Oct-23-23 01:00AM	Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress (GlobeNewswire) -5.05%
Oct-03-23 04:30PM	IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting (GlobeNewswire) +10.22%
Sep-12-23 08:05AM	IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer (GlobeNewswire) -13.20%
Sep-06-23 08:35AM	IO Biotech Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-17-23 08:59AM	10 Best New Penny Stocks to Buy Now (Insider Monkey)
Aug-16-23 09:01PM	Stonepine Capital Management, LLC Acquires New Stake in IO Biotech Inc (GuruFocus.com)
Aug-11-23 08:30AM	IO Biotech Announces 2023 Second Quarter Results (GlobeNewswire)
08:05AM	IO Biotech Appoints Heidi Hunter to its Board of Directors (GlobeNewswire)
Aug-08-23 08:05AM	IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023 (GlobeNewswire)
Aug-07-23 08:30AM	IO Biotech, Inc. Announces $75 Million Private Placement Financing (GlobeNewswire)
Jul-28-23 08:05AM	IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center (GlobeNewswire)
Jul-25-23 04:05PM	IO Biotech Announces Abstract Accepted for Mini Oral Presentation at IASLC 2023 World Conference on Lung Cancer (GlobeNewswire)
Jul-18-23 04:05PM	IO Biotech Strengthens Executive Management and US Presence with Appointment of Qasim Ahmad, MD, as Chief Medical Officer (GlobeNewswire)
Jun-15-23 09:55AM	2 Strong Buy Penny Stocks That Could Rally Over 300% (TipRanks) +27.33%
08:18AM	IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study (Zacks)
Jun-14-23 12:42PM	Why Are IO Biotech Shares Trading Lower Today (Benzinga) -26.48%
08:00AM	IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone (GlobeNewswire)
Jun-01-23 08:30AM	IO Biotech Appoints Christine Richter, Ph.D., MBA, as Senior Vice President, Commercial and Program Lead (GlobeNewswire)
May-30-23 04:35PM	IO Biotech to Present at the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 04:05PM	IO Biotech Announces 2023 First-Quarter Results (GlobeNewswire) +9.69% -7.91%
May-02-23 07:22AM	Is IO Biotech (NASDAQ:IOBT) In A Good Position To Invest In Growth? (Simply Wall St.)
Mar-22-23 06:14AM	The Chief Financial Officer of IO Biotech, Inc. (NASDAQ:IOBT), Amy Sullivan, Just Bought A Few More Shares (Simply Wall St.)
Mar-14-23 04:11PM	IO Biotech Announces 2022 Fourth-Quarter and Year-End Results (GlobeNewswire) -7.79%
Feb-22-23 07:00AM	IO Biotech to Participate in March 2023 Investor Conferences (GlobeNewswire)
Jan-23-23 08:00AM	IO Biotech Announces Appointment of Devin Smith as General Counsel (GlobeNewswire)
Jan-09-23 07:05AM	IO Biotech Provides Business Update (GlobeNewswire)
Nov-21-22 01:23PM	Analyst Says IO Biotech's Cancer Treatment Approach 'Differentiated' (Benzinga) -12.11%
Nov-09-22 04:07PM	IO Biotech Announces an Invited Oral Presentation and Two Poster Presentations with New Preclinical Data for Additional Pipeline Candidates at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire) +16.73%
04:05PM	IO Biotech Announces Third Quarter Results for 2022 (GlobeNewswire)
Nov-03-22 08:00AM	IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors (GlobeNewswire)
Oct-31-22 08:00AM	IO Biotech to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)

IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hunter Heidi	Director	May 30 '25	Buy	1.39	15,000	20,884	15,000	Jun 02 07:53 AM
Ahmad Qasim Iftikhar	Chief Medical Officer	Dec 23 '24	Buy	0.85	31,350	26,553	31,350	Dec 26 08:50 AM
Zocca Mai-Britt	Chief Executive Officer	Dec 23 '24	Buy	0.81	12,500	10,120	49,891	Dec 23 06:56 PM
Sullivan Amy	Chief Financial Officer	Dec 23 '24	Buy	0.83	10,250	8,483	84,632	Dec 23 06:53 PM
Smith Devin Whittemore	General Counsel	Dec 23 '24	Buy	0.81	12,000	9,720	16,938	Dec 23 06:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

IOBT

IO Biotech Inc

Upgrade your FINVIZ experience